UiPath (NYSE:PATH) Rated ‘Neutral’ by Bank of America

Bank of America maintained its neutral rating on the company’s shares UiPath (NYSE:PATH – Free Report) in a research report published Thursday morning, Marketbeat.com reports. Bank of America now has a $16.00 price target on shares of this healthcare company, up from a prior price target of $30.00.

Other analysts have also recently published reports on the company. Barclays increased their price target on UiPath from $23.00 to $25.00 and gave the company an equal rating in a report on Friday, March 15th. Canaccord Genuity Group increased their price target on UiPath from $27.00 to $30.00 and gave the company a “buy” rating in a report on Friday, March 15. Morgan Stanley increased their price target on UiPath from $17.00 to $25.00 and gave the company the same rating in a research note on Thursday, March 14th. In a research note issued on Thursday, March 14, JPMorgan Chase & Co. upgraded UiPath from a neutral rating to an overweight rating and raised its price target for the company from $22.00 to $28.00. Finally, Wells Fargo & Company upped their price target on UiPath from $24.00 to $25.00 and gave the stock the same rating in a research note on Thursday, March 14th. Fifteen investment analysts have rated the company with a hold rating and three have rated the company with a buy rating. According to MarketBeat.com, UiPath currently has a consensus rating of Hold and a consensus price target of $20.24.

See our latest analysis on UiPath

UiPath trading drops 34.0%

On Thursday, NYSE:PATH began trading at $12.07. UiPath has a twelve month low of $11.71 and a twelve month high of $27.87. The stock has a fifty-day simple moving average of $20.13 and a 200-day simple moving average of $22.06.

UiPath (NYSE:PATH – Get Free Report) last released its quarterly data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, $0.10 above the consensus estimate of ($0.04). The company had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative return on equity of 2.99% and a negative net margin of 6.41%. Research analysts forecast that UiPath will post -0.04 earnings per share for the current fiscal year.

Confidential activity on UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the transaction, the CFO now directly owns 87,505 shares of the company’s stock valued at $1,998,614.20. The sale was disclosed in a filing with the Securities and Exchange Commission, available at this hyperlink. In the last quarter, insiders sold a total of 96,000 shares of company stock worth $2,023,440. Insiders own 22.37% of the company’s shares.

Institutional inflows and outflows

Many large investors have recently bought and sold shares of the company. Intech Investment Management LLC increased its holdings in UiPath by 3.1% during the 4th quarter. After acquiring an additional 426 shares during the period, Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000. 180 Wealth Advisors LLC increased its holdings in shares of UiPath by 0.3% during the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after purchasing an additional 492 shares during the period. Global Financial Private Client LLC increased its holdings in shares of UiPath by 9.3% during the first quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after purchasing an additional 551 shares during the period. Bleakley Financial Group LLC increased its holdings in shares of UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the health care company’s stock valued at $315,000 after purchasing an additional 598 shares during the period. Finally, Simplicity Solutions LLC increased its holdings in UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after purchasing an additional 598 shares during the period. The owners of 62.50% of the shares are institutional investors and hedge funds.

About UiPath

(Get the free report)

UiPath Inc provides a comprehensive automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands and around the world. The company offers a suite of related software to create, manage, enable, engage, measure and manage automation within an organization.

UiPath trading drops 34.0%

Confidential activity on UiPath

Institutional inflows and outflows

About UiPath

See also